China
Africa
Explore chapters and articles related to this topic
Drug-induced hypopigmentation
Published in Electra Nicolaidou, Clio Dessinioti, Andreas D. Katsambas, Hypopigmentation, 2019
Katerina Damevska, Suzana Nikolovska, Razvigor Darlenski, Ljubica Suturkova, Torello Lotti
A few case reports have documented vitiligo-like depigmentation and poliosis associated with imiquimod treatment. This side effect has been reported in imiquimod treatment of genital warts (Figure 23.4), verruca vulgaris, molluscum contagiosum, basal cell carcinoma, lentigo maligna, and extramammary Paget disease.39–41 Depigmentation is rarely associated with imiquimod use for the treatment of actinic keratoses, which may be due to the twice-weekly dosing regimen.40
Verrucous carcinoma
Published in Longo Caterina, Diagnosing the Less Common Skin Tumors, 2019
Palmoplantar VC occurs predominantly on the soles (Figure 4.2) and on the anterior weight-bearing areas, but can occur also on the palms (Figure 4.3). It usually appears as a fungating, exophytic mass with numerous keratin-filled sinuses. As the tumor grows, it locally invades soft tissues until reaching the plantar fascia and advances toward the dorsal surface of the foot, with destruction of the metatarsal bones occurring.5,14 A history of a nonhealing wart on the soles, palms or other locations should raise suspicion of VC and lead the physician to perform a biopsy. A deep biopsy specimen of the lesion is necessary, as superficial portions may resemble a verruca vulgaris.
An Overview of Microbes Pathogenic for Humans
Published in Nancy Khardori, Bench to Bedside, 2018
Eric Lehrer, James Radike, Nancy Khardori
Human papillomavirus (HPV): there are roughly 150 known viruses that belong to this group (Bernard et al. 2010). HPV serotypes 1 and 4 are responsible for skin warts, commonly known as verruca vulgaris, which are transmitted by close physical contact. HPV serotypes 6 and 11 are responsible for genital warts, known as condyloma accuminatum. HPV serotypes 16 and 18 are associated with squamous cell carcinoma of the cervix and anus.
Intralesional injection of vitamin D in verruca vulgaris increases cathelicidin (LL37) expression; therapeutic and immunohistochemical study
Published in Journal of Dermatological Treatment, 2022
Neveen E. Sorour, Fatma M. Elesawy, Asmaa G. Abdou, Sara E. Abdelazeem, Essam M. Akl
This study was approved by the local Ethics Committee of Research involving human subjects of Benha Faculty of Medicine in November 2017 and registered under number D89/2017. The study included 20 patients of both sexes suffering from verruca vulgaris recruited from the Out-patient Clinic of Dermatology, Venereology and Andrology Department, Benha University Hospital in the period between January 2018 and January 2019. In addition, 10 healthy individuals who were attending Plastic Surgery Outpatient Clinic, Benha University were included as a control group. Written informed consent was obtained from each participant in the study. Patients included in this study were above the age of 18 years, suffering from multiple verruca vulgaris (≥3verrucae vulgaris). The size of the verrucae was sufficient for taking the biopsy and intralesional injection (more than 4 mm). No topical or systemic treatment for verrucae had been applied 4 weeks before the injection of vitamin D3. We excluded patients with a history of an allergic response to vitamin D, pregnant and lactating females, hepatic and renal patients and patients with a history of disorders in calcium metabolism.
Evaluation of combined treatment with long-pulsed neodymium-doped yttrium aluminum garnet laser and potassium hydroxide for the treatment of recalcitrant wart: a prospective comparative study
Published in Journal of Dermatological Treatment, 2020
Fathia M. Khattab, Shrook A. Khashaba
In a more extensive series, Han et al. treated recalcitrant warts in 369 patients with slightly overlapping pulses with a 1064-nm LP Nd:YAG laser with a fluence of 200 J/cm2 (11). Clearance rates of the treated lesions after four treatment sessions at 4-week intervals were 65, 83, 92, and 96%, with an overall success rate of 96%. Verruca vulgaris responded more favorably after a single treatment with a clearance rate of 72.6%, compared to the 44.1% reported for deep palmoplantar warts. The relatively easy access of verruca vulgaris may attribute to the fewer number of treatments for clearance in comparison to deep palmoplantar warts, 1.35 and 1.95 sessions. The higher fluence used by this study could be a significant factor in the high success of clearance. However, the combination of a 20-ms duration time and a fluence setting at the upper limit of the effective range presented adverse effects on patients such as transient numbness (15%), hemorrhagic bullae (7%), hyperpigmentation (5%), hypopigmentation (4%), and nail dystrophy (2%).
A comprehensive review of treatment options for recalcitrant nongenital cutaneous warts
Published in Journal of Dermatological Treatment, 2022
Kanchana Leerunyakul, Sasima Thammarucha, Poonkiat Suchonwanit, Suthinee Rutnin
Cutaneous warts are a common dermatological condition caused by human papillomavirus (HPV). More than 100 HPV genotypes have been identified to date. The occurrence of disease widely varies based on different age groups and populations, with an estimated prevalence of up to 33% in primary schoolchildren and up to 22% in the general population (1,2). HPV-associated warts are diagnosed based on anatomical location or morphology such as common warts (verruca vulgaris), flat warts (verruca plana), plantar warts (verruca plantaris), periungual warts, and genital warts (condyloma acuminata) (3). Most patients with cutaneous warts require treatment due to cosmetic disfigurement as well as functional and social concerns.